Anti-diabetic effect of a leaf extract from Gymnema sylvestre in non-insulin-dependent diabetes mellitus patients - https://www.ncbi.nlm.nih.gov/pubmed?term=Baskaran%20K%20et%20al.%20Antidiabetic%20effect%20of%20a%20leaf%20extract%20from%20gymnema%20sylvestre%20in%20non-insulin-dependent%20diabetes%20mellitus%20patients Possible regeneration of the islets of langerhans in streptozotocin-diabetic rats given gymnema sylvestre leaf extracts - http://www.sciencedirect.com/science/article/pii/0378874190901064 Effects of a cinnamon extract on plasma glucose, HbA1c, and serum lipids in diabetes mellitus type 2 - http://onlinelibrary.wiley.com/doi/10.1111/j.1365-2362.2006.01629.x/full Effectiveness of Cinnamon for Lowering Hemoglobin A1C in Patients with Type 2 Diabetes: A Randomized, Controlled Trial - http://www.jabfm.org/content/22/5/507.short Cloves protect the heart, liver and lens of diabetic rats - http://www.sciencedirect.com/science/article/pii/S0308814610003870 Cloves improve glucose, cholesterol and triglycerides of people with type 2 diabetes mellitus - http://www.fasebj.org/content/20/5/A990.3.short Effects of rosemary on lipid profile in diabetic rats - http://www.academicjournals.org/article/article1380120780_Aljamal%20et%20al.pdf Inhibition of Advanced Glycation End-Product Formation by Origanum majorana L. In Vitro and in Streptozotocin-Induced Diabetic Rats - https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3447365/ Evaluation of clonal herbs of Lamiaceae species for management of diabetes and hypertension - http://apjcn.org/update%5Cpdf%5C2006%5C1%5C107%5C107.pdf Metformin-like effect of Salvia officinalis (common sage): is it useful in diabetes prevention? - https://www.ncbi.nlm.nih.gov/pubmed/16923227 Antidiabetic effect of garlic (Allium sativum L.) in normal and streptozotocin-induced diabetic rats - http://www.sciencedirect.com/science/article/pii/S0944711305002175 Antiglycation Properties of Aged Garlic Extract: Possible Role in Prevention of Diabetic Complications - http://jn.nutrition.org/content/136/3/796S.full#fn-1 Effect of ethanolic extract of Zingiber officinale on dyslipidaemia in diabetic rats - http://www.sciencedirect.com/science/article/pii/S0378874104005732 Effect of Ginger Extract Consumption on levels of blood Glucose, Lipid Profile and Kidney Functions in Alloxan Induced-Diabetic Rats - http://s3.amazonaws.com/academia.edu.documents/35273868/17.pdf?AWSAccessKeyId=AKIAJ56TQJRTWSMTNPEA&Expires=1484639718&Signature=Zb4rY42u7WJrbngfV6pCQzu61e0%3D&response-content-disposition=inline%3B%20filename%3DEffect_of_Ginger_Extract_Consumption_on.pdf Efficacy of turmeric on blood sugar and polyol pathway in diabetic albino rats - http://link.springer.com/article/10.1023/A:1013106527829 Hypolipidemic action of curcumin, the active principle of turmeric (Curcuma longa) in streptozotocin induced diabetic rats - http://link.springer.com/article/10.1023/A:1006819605211 A REVIEW ON ROLE OF MURRAYA KOENIGII (CURRY LEAF) IN (DIABETES MELLITUS – TYPE II) PRAMEHA - http://www.journalijdr.com/sites/default/files/4740.pdf Capsaicin and glucose absorption and utilization in healthy human subjects - https://www.ncbi.nlm.nih.gov/pubmed/16612838 Inhibition of Advanced Glycation End-Product Formation by Origanum majorana L. In Vitro and in Streptozotocin-Induced Diabetic Rats - https://www.ncbi.nlm.nih.gov/pubmed/23008741 Use of Fenuqreek seed powder in the management of non-insulin dependent diabetes mellitus - http://www.sciencedirect.com/science/article/pii/0271531796001418 Ginseng and Diabetes: The Evidences from In Vitro, Animal and Human Studies - http://citeseerx.ist.psu.edu/viewdoc/download?doi=10.1.1.797.4558&rep=rep1&type=pdf
The vast majority of people with diabetes, on the other hand, have the type 2 form, which is sometimes referred to as adult-onset diabetes, even though more and more children these days are developing this type. Lifestyle changes can play a vital role in controlling type 2; they are generally the initial and preferred method for regulating blood sugar levels, although oral medication and even insulin may eventually need to be added to the treatment regimen.
As of 2015 the guidelines called for an HbA1c of around 7% or a fasting glucose of less than 7.2 mmol/L (130 mg/dL); however these goals may be changed after professional clinical consultation, taking into account particular risks of hypoglycemia and life expectancy. Despite guidelines recommending that intensive blood sugar control be based on balancing immediate harms and long-term benefits, many people – for example people with a life expectancy of less than nine years – who will not benefit are over-treated and do not experience clinically meaningful benefits.
As of now, diabetes is classified as either Type I or Type II. New research suggests there are several more types of diabetes, which all require different treatment approaches, but that’s a developing area of knowledge. On an episode of Bulletproof Radio, Dr. Steven Masley explains why doctors are starting to view Altzheimer’s disease as “type III diabetes” and picks apart the relationship between insulin and brain degeneration. Listen to it on iTunes.
An injection port has a short tube that you insert into the tissue beneath your skin. On the skin’s surface, an adhesive patch or dressing holds the port in place. You inject insulin through the port with a needle and syringe or an insulin pen. The port stays in place for a few days, and then you replace the port. With an injection port, you no longer puncture your skin for each shot—only when you apply a new port.
Glycated hemoglobin (A1C) test. This blood test indicates your average blood sugar level for the past two to three months. It measures the percentage of blood sugar attached to hemoglobin, the oxygen-carrying protein in red blood cells. The higher your blood sugar levels, the more hemoglobin you'll have with sugar attached. An A1C level of 6.5 percent or higher on two separate tests indicates you have diabetes. A result between 5.7 and 6.4 percent is considered prediabetes, which indicates a high risk of developing diabetes. Normal levels are below 5.7 percent.
Any food that you ingest is processed and metabolized by the body. Food is broken down into the various building blocks the body needs, and what cannot be metabolized or used is processed and removed by the liver. Protein and fats are used for muscle and tissue regeneration and other processes in the body. Carbohydrates are typically a fast fuel for the body, but when more are eaten that the body immediately needs, they must be stored. A simple explanation from a previous post:
Acupuncture is a procedure where a practitioner inserts very thin needles into specific points on your skin. Some scientists say that acupuncture triggers the release of the body's natural painkillers. Acupuncture has been shown to offer relief from chronic pain and is sometimes used by people with neuropathy, the painful nerve damage that can happen with diabetes.
Within the hepatocyte, fatty acids can only be derived from de novo lipogenesis, uptake of nonesterified fatty acid and LDL, or lipolysis of intracellular triacylglycerol. The fatty acid pool may be oxidized for energy or may be combined with glycerol to form mono-, di-, and then triacylglycerols. It is possible that a lower ability to oxidize fat within the hepatocyte could be one of several susceptibility factors for the accumulation of liver fat (45). Excess diacylglycerol has a profound effect on activating protein kinase C epsilon type (PKCε), which inhibits the signaling pathway from the insulin receptor to insulin receptor substrate 1 (IRS-1), the first postreceptor step in intracellular insulin action (46). Thus, under circumstances of chronic energy excess, a raised level of intracellular diacylglycerol specifically prevents normal insulin action, and hepatic glucose production fails to be controlled (Fig. 4). High-fat feeding of rodents brings about raised levels of diacylglycerol, PKCε activation, and insulin resistance. However, if fatty acids are preferentially oxidized rather than esterified to diacylglycerol, then PKCε activation is prevented, and hepatic insulin sensitivity is maintained. The molecular specificity of this mechanism has been confirmed by use of antisense oligonucleotide to PKCε, which prevents hepatic insulin resistance despite raised diacylglycerol levels during high-fat feeding (47). In obese humans, intrahepatic diacylglycerol concentration has been shown to correlate with hepatic insulin sensitivity (48,49). Additionally, the presence of excess fatty acids promotes ceramide synthesis by esterification with sphingosine. Ceramides cause sequestration of Akt2 and activation of gluconeogenic enzymes (Fig. 4), although no relationship with in vivo insulin resistance could be demonstrated in humans (49). However, the described intracellular regulatory roles of diacylglycerol and ceramide are consistent with the in vivo observations of hepatic steatosis and control of hepatic glucose production (20,21).
A useful test that has usually been done in a laboratory is the measurement of blood HbA1c levels. This is the ratio of glycated hemoglobin in relation to the total hemoglobin. Persistent raised plasma glucose levels cause the proportion of these molecules to go up. This is a test that measures the average amount of diabetic control over a period originally thought to be about 3 months (the average red blood cell lifetime), but more recently[when?] thought to be more strongly weighted to the most recent 2 to 4 weeks. In the non-diabetic, the HbA1c level ranges from 4.0–6.0%; patients with diabetes mellitus who manage to keep their HbA1c level below 6.5% are considered to have good glycemic control. The HbA1c test is not appropriate if there has been changes to diet or treatment within shorter time periods than 6 weeks or there is disturbance of red cell aging (e.g. recent bleeding or hemolytic anemia) or a hemoglobinopathy (e.g. sickle cell disease). In such cases the alternative Fructosamine test is used to indicate average control in the preceding 2 to 3 weeks.
Like the sulfonylureas, meglitinides is a class of drugs that work by promoting insulin secretion from the pancreas. Unlike the sulfonylureas, which last longer in the body, repaglinide (Prandin) and nateglinide (Starlix) are very short acting, with peak effects within one hour. For this reason, they are given up to three times a day just before meals.